Developing new drugs to fight cancer by targeting a specific protein process
Discovery and anti-tumor activity of the first antagonists targeting human Sonic Hedgehog autoprocessing
['FUNDING_R21'] · STATE UNIVERSITY OF NY,BINGHAMTON · NIH-11051241
This study is looking for new small molecules that can help stop cancer growth by targeting a special protein called Sonic Hedgehog, and it's testing these potential treatments on cancer cells from patients with multiple myeloma and colon cancer to find better options for them.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STATE UNIVERSITY OF NY,BINGHAMTON (nih funded) |
| Locations | 1 site (BINGHAMTON, UNITED STATES) |
| Trial ID | NIH-11051241 on ClinicalTrials.gov |
What this research studies
This research focuses on creating small molecules that can inhibit a unique process in cancer cells involving the Sonic Hedgehog protein, which is crucial for tumor growth. The team has developed a high-throughput screening method to identify these potential drug-like compounds. By testing these compounds on human cancer cells, particularly those related to multiple myeloma and colon cancer, the research aims to evaluate their effectiveness in stopping tumor growth. Patients may benefit from new treatment options that specifically target the underlying mechanisms of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with multiple myeloma or colon cancer that depend on Sonic Hedgehog signaling for growth.
Not a fit: Patients with cancers that do not involve Sonic Hedgehog signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that effectively combat specific types of cancer.
How similar studies have performed: While targeting the Sonic Hedgehog pathway has been explored, this specific approach using autoprocessing antagonists is novel and has not been extensively tested.
Where this research is happening
BINGHAMTON, UNITED STATES
- STATE UNIVERSITY OF NY,BINGHAMTON — BINGHAMTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CALLAHAN, BRIAN PATRICK — STATE UNIVERSITY OF NY,BINGHAMTON
- Study coordinator: CALLAHAN, BRIAN PATRICK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer, anti-cancer therapeutic, anticancer activity